Figure 1.

Comparison of relative frequencies of circulating immune effector subsets between relapsed and non-relapsed patients at the moment of TKI discontinuation. (A) Frequencies of NK cells, defined as CD3(-)CD56(+) cells, among live lymphocytes from relapsed (n=4) and non-relapsed (n=18) patients. Healthy control donors (HD) mean: 17.3% ± 8.1% (n=11). (B) Frequencies of total CD8 T cells among live lymphocytes (left panel) and of EMRA, Naive, EM, and CM cells based on the expression of CD45RA and/or CCR7 among total CD8 T-cells, defined as TCR-αβ(+)CD8(+) cells (right panel), from relapsed (n=7) and non-relapsed (n=19) patients. HD means: 19% ± 5.6% of CD8-T cells among live lymphocytes; 24.4% ± 5.4% of EMRA cells, 24.6% ± 18.6% of Naive cells, 10.6% ± 5.7% of CM cells, 40.5% ± 14.3% of EM cells among total CD8 T-cells (n=11). Of note, for EM cells, differences were significant between HD and non-relapsed patients (p-value: 0.002). (C) Frequencies of innate CD8-T cells, defined as TCR-αβ(+)CD8(+) Eomes(+)KIR/NKG2A(+), among total CD8 T-cells from relapsed (n=7) and non-relapsed (n=18) patients. HD mean: 5.5% ± 7.4% (n=13). (D) Frequencies of iNKT cells, defined as CD3(+)TCR-Vα24-Jα18(+), among live lymphocytes from relapsed (n=5) and non-relapsed (n=18) patients. HD mean: 0.15% ± 0.2% (n=11). (E) Frequencies of γδ T-cells, defined as CD3(+)TCR-pan-γδ(+), among live lymphocytes from relapsed (n=5) and non-relapsed (n=18) patients. HD mean: 3.5% ± 2.9% (n=11). Representative dot plots show relative frequencies of the different populations of interest in relapsed (top left) and non-relapsed (bottom left) patients. Histograms represent cohort analysis of relative population frequencies (mean ± SD). Each dot represents a relapsed (red squares) or a non-relapsed (blue triangles) patient. Dotted lines represent relative frequency mean for each population of interest in HD. Statistical significance was determined by the two-tailed Mann-Whitney non-parametric test, ns: not significant.